A new Alzheimer’s drug has proven to be highly successful in directly preventing the disease. Photo: File
Washington: The Food and Drug Administration (FDA), the US drug approval agency, has approved the first drug to slow Alzheimer’s disease.
Although it is an expensive drug with an annual cost of $26,000. This drug called ‘Lacombe’ is manufactured by the Japanese company Isai which is sold under the brand name of Lisenmib. It is injected into the body through the veins, which prevents the accumulation of amyloid components in the brain. It has been proven that leprosy is the main cause of Alzheimer’s disease. The more amyloid accumulates, the more Alzheimer’s disease progresses.
Early experiments have shown that long-term use of this drug can reduce amyloid in the brain by 27%, which is an extraordinary development. Thus, this drug can benefit 6 million people in the US alone who are caught in this condition.
But early trials have revealed some very dangerous side effects of the drug that may overshadow its benefits. Out of a total of 1795 people who used this drug, 17% of them developed brain swelling and internal bleeding. This is why there will be a need for scanning and constant monitoring of drug users.
The rest of the people complained of headache, but the brain swelling subsided and returned to normal after some time. Despite all this, it is an important drug that directly controls the cause of Alzheimer’s.
(function(d, s, id){
var js, fjs = d.getElementsByTagName(s)[0];
if (d.getElementById(id)) {return;}
js = d.createElement(s); js.id = id;
js.src = “//connect.facebook.net/en_US/sdk.js#xfbml=1&version=v2.3&appId=770767426360150”;
fjs.parentNode.insertBefore(js, fjs);
}(document, ‘script’, ‘facebook-jssdk’));
(function(d, s, id) {
var js, fjs = d.getElementsByTagName(s)[0];
if (d.getElementById(id)) return;
js = d.createElement(s); js.id = id;
js.src = “//connect.facebook.net/en_GB/sdk.js#xfbml=1&version=v2.7”;
fjs.parentNode.insertBefore(js, fjs);
}(document, ‘script’, ‘facebook-jssdk’));